|
Combination Chemotherapy After Surgery With or Without Chinese Herbal Therapy to Treat Symptoms in Women With Breast Cancer Clinical Trials Information presented on Clinical Trials Search is not intended to be a substitute for qualified health advice, trips or treatment by using a genuine doctor. We aren't doctors. Always consult your mD on Combination Chemotherapy After Surgery With or Without Chinese Herbal Therapy to Treat Symptoms in Women With Breast Cancer conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Combination Chemotherapy After Surgery With or Without Chinese Herbal Therapy to Treat Symptoms in Women With Breast Cancer Clinical research trials and Combination Chemotherapy After Surgery With or Without Chinese Herbal Therapy to Treat Symptoms in Women With Breast Cancer health trials take place in a lot of of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / projects is to answer specific human medical questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, like Combination Chemotherapy After Surgery With or Without Chinese Herbal Therapy to Treat Symptoms in Women With Breast Cancer. Combination Chemotherapy After Surgery With or Without Chinese Herbal Therapy to Treat Symptoms in Women With Breast Cancer Clinical Trials and other clinical trials allow for volunteers to have health treatment alternatives before they are available to the general public. Many times the test subjects obtain treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Combination Chemotherapy After Surgery With or Without Chinese Herbal Therapy to Treat Symptoms in Women With Breast Cancer clinical trial. Subjects oftentimes recieve the most effective healthcare possible for their Combination Chemotherapy After Surgery With or Without Chinese Herbal Therapy to Treat Symptoms in Women With Breast Cancer condition. Hazards are a reality, however, and could include additional or frequent doctor visits, healthcare dangers (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Combination Chemotherapy After Surgery With or Without Chinese Herbal Therapy to Treat Symptoms in Women With Breast Cancer  Combination Chemotherapy After Surgery With or Without Chinese Herbal Therapy to Treat Symptoms in Women With Breast Cancer
Combination Chemotherapy After Surgery With or Without Chinese Herbal Therapy to Treat Symptoms in Women With Breast Cancer
For Condition: Drug Toxicity,recurrent breast cancer,stage 2 breast cancer,stage 1 breast cancer,stage 3A breast cancer
Status: No longer recruiting
Sponsor(s): University of California, San Francisco , National Cancer Institute (NCI)
Synopsis: RATIONALE: Herbs used in traditional Chinese medicine may decrease the side effects of chemotherapy. PURPOSE: Randomized phase I/II trial to study the effectiveness of herbs used in traditional Chinese medicine in decreasing the side effects of chemotherapy after surgery in women who have stage I, stage II, or early stage III breast cancer.
Details: OBJECTIVES: - Determine the toxic effects and safety of chinese herbal therapy (CHT) when administered for toxicity attenuation in combination with adjuvant doxorubicin and cyclophosphamide in women with stage I, II, or early stage III breast cancer. - Determine patient compliance and the feasibility of using CHT by daily treatment calendars, weekly symptom inventories, and quality of life and mood state questionnaires completed by these patients. - Determine patient preferences and concerns about CHT. - Determine, preliminarily, the efficacy of CHT in ameliorating the toxic effects/side effects of adjuvant chemotherapy with doxorubicin and cyclophosphamide, in terms of the incidence and severity of adverse events, in these patients. OUTLINE: This is a randomized, placebo-controlled, double-blind study. Patients are randomized to one of two treatment arms. - Arm I: Patients receive adjuvant doxorubicin IV and cyclophosphamide IV over 1 hour on days 0, 21, 42, and 63. Patients also receive oral chinese herbal therapy three times daily on days -10 to 105. - Arm II: Patients receive adjuvant chemotherapy as in arm I and oral placebo three times daily on days -10 to 105. Quality of life is assessed at baseline and on days 3, 24, 45, 66, 84, and 105. Patients are followed at day 105. PROJECTED ACCRUAL: A total of 60 patients (30 per treatment arm) will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed stage I, II, or early stage III breast cancer for which adjuvant doxorubicin and cyclophosphamide is recommended - No metastatic disease - Hormone receptor status: - Not specified PATIENT CHARACTERISTICS: Age: - Over 18 Sex: - Female Menopausal status: - Not specified Performance status: - Karnofsky 80-100% Life expectancy: - Not specified Hematopoietic: - WBC at least 3,000/mm^3 - Absolute neutrophil count at least 1,500/mm^3 - Hemoglobin at least 9.0 g/dL - Platelet count at least 100,000/mm^3 Hepatic: - Bilirubin no greater than 1.5 mg/dL - AST no greater than 2 times normal Renal: - Creatinine no greater than 1.5 mg/dL Cardiovascular: - No evidence of acute ischemic cardiac disease on ECG Other: - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No history of multiple severe food or medicine allergies or sensitivities - No medical or psychological condition that would preclude study participation - No severe concurrent illness PRIOR CONCURRENT THERAPY: Biologic therapy: - No concurrent immunotherapy Chemotherapy: - See Disease Characteristics - No other concurrent chemotherapy Endocrine therapy: - No concurrent hormonal therapy Radiotherapy: - At least 3 weeks since prior radiotherapy - No concurrent radiotherapy Surgery: - Not specified Other: - At least 3 weeks since prior investigational agents - At least 3 weeks since prior herbal therapy - No other concurrent investigational agents - No other concurrent herbal therapy or alternative medicine - Concurrent acupuncture allowed
Total Enrollment:
Location and Contact Information:
Overall Study Official:
HopeRugo, Study Chair, University of California, San Francisco
UCSF Comprehensive Cancer Center
San Francisco, California, 94115-1710
United States
Additional Information:
Study ID Numbers: CDR0000069154; UCSF-CRO-97755,UCSF-IND-54870,NCI-G01-2042
Study Start Date:
Record last reviewed: October 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00028964
Other Recurrent Breast Cancer Studies:
1. Tipifarnib and Fulvestrant as Second-Line Therapy in Treating Postmenopausal Women With Hormone Receptor-Positive Inoperable Locally Advanced or Metastatic Breast Cancer With Progressive Disease After Previous First-Line Endocrine Therapy
2. PS-341 in Treating Women With Metastatic Breast Cancer
3. Flavopiridol Plus Cisplatin or Carboplatin in Treating Patients With Advanced Solid Tumors
4. Bryostatin 1 in Treating Patients With Stage IV Breast Cancer
5. SU5416 and Doxorubicin in Treating Patients With Stage IIIB or Stage IV Inflammatory Breast Cancer
Related Studies:
Other recurrent breast cancer Clinical Trials
Other California Clinical Trials
Other San Francisco Clinical Trials
Combination Chemotherapy After Surgery With or Without Chinese Herbal Therapy to Treat Symptoms in Women With Breast Cancer
|
|
|
|
|
|
|
|
